{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:01:28Z","timestamp":1787320888849,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":538,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016477","name":"CareDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016477","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jtct.2021.08.017","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:48:19Z","timestamp":1630536499000},"page":"990.e1-990.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4504-398X","authenticated-orcid":false,"given":"Kuo-Kai","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-2404","authenticated-orcid":false,"given":"Eno-Abasi","family":"Inyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Romee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasweta","family":"Gooptu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Antin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Soiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-4314","authenticated-orcid":false,"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.08.017_bib0001","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.08.017_bib0002","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1182\/blood-2010-12-323824","article-title":"Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis","volume":"117","author":"Arora","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.08.017_bib0003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry","volume":"341","author":"Soci\u00e9","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.08.017_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2016-08-686659","article-title":"Mechanistic approaches for the prevention and treatment of chronic GVHD","volume":"129","author":"Cutler","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.08.017_bib0005","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.bbmt.2008.09.017","article-title":"Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease","volume":"14","author":"Flowers","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.08.017_bib0006","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2021.08.017_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jtct.2021.08.017_bib0008","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.08.017_bib0009","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.humimm.2019.03.003","article-title":"Sarantopoulos S. B cells in chronic graft-versus-host disease","volume":"80","author":"McManigle","year":"2019","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jtct.2021.08.017_bib0010","unstructured":"Mammadli M, Huang W, Harris R, et al. Inhibition of ITK differentiates GVT and GVHD in allo-HSCT. bioRxiv [preprint]. July 15, 2020. doi:10.1101.2020.07.15.204693."},{"key":"10.1016\/j.jtct.2021.08.017_bib0011","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.08.017_bib0012","unstructured":"U.S. Food & Drug Administration. FDA expands ibrutinib indications to chronic GVHD. 2017. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-ibrutinib-indications-chronic-gvhd. Accessed September 15, 2020."},{"key":"10.1016\/j.jtct.2021.08.017_bib0013","unstructured":"U.S. Food & Drug Administration. FDA approves belumosudil for chronic graft-versus-host disease. 2021. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-belumosudil-chronic-graft-versus-host-disease. Accessed July 22, 2021."},{"issue":"15_suppl","key":"10.1016\/j.jtct.2021.08.017_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7072","article-title":"A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease","volume":"35","author":"Miklos","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.08.017_bib0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","article-title":"Ruxolitinib as salvage therapy for chronic graft-versus-host disease","volume":"25","author":"Modi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.08.017_bib0016","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.08.017_bib0017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbmt.2019.09.002","article-title":"Carfilzomib for treatment of refractory chronic graft-versus-host disease: a Chronic GVHD Consortium pilot phase II trial","volume":"26","author":"Pidala","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.08.017_bib0018","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood-2018-04-785899","article-title":"How I treat refractory chronic graft-versus-host disease","volume":"133","author":"Sarantopoulos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.08.017_bib0019","series-title":"62nd ASH Annual Meeting and Exposition","article-title":"Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: the Rockstar Study (KD025-213)","author":"Cutler","year":"2020"},{"key":"10.1016\/j.jtct.2021.08.017_bib0020","series-title":"62nd ASH Annual Meeting and Exposition","article-title":"Phase 1 study of axatilimab (SNDX-6352), a CSF-1R humanized antibody, for chronic graft-versus-host disease after 2 or more lines of systemic treatment","author":"Arora","year":"2020"},{"key":"10.1016\/j.jtct.2021.08.017_bib0021","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.08.017_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.05.019","article-title":"An open-label, single-arm, multicenter study of ibrutinib in Japanese patients with steroid-dependent\/refractory chronic graft-versus-host disease","author":"Doki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2021.08.017_bib0023","first-page":"18","article-title":"OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine","volume":"6","author":"Orechia","year":"2015","journal-title":"Appl Transl Genom"},{"key":"10.1016\/j.jtct.2021.08.017_bib0024","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.08.017_bib0025","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.08.017_bib0026","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report","volume":"12","author":"Pavletic","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.08.017_bib0027","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.08.017_bib0028","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.08.017_bib0029","unstructured":"Miklos D, Abu Zaid M, Cooney JP, et al. Ibrutinib vs placebo in combination with corticosteroids in patients with new-onset chronic graft-versus-host disease (cGVHD): results from the randomized, double-blind phase 3 iNTEGRATE study. European Hematology Association 2021:abstrS235. Available at: https:\/\/library.ehaweb.org\/eha\/2021\/. Accessed Sept 1, 2021."},{"key":"10.1016\/j.jtct.2021.08.017_bib0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41409-020-01122-8","article-title":"Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease","volume":"56","author":"Maas-Bauer","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.08.017_bib0031","series-title":"At: 62nd ASH Annual Meeting and Exposition","article-title":"Ruxolitinib (RUX) vs best available therapy (BAT) in patients with steroid-refractory\/steroid-dependent chronic graft-vs-host disease (cGVHD): primary findings from the phase 3, randomized REACH3 study","author":"Zeiser","year":"2020"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721011660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721011660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:03Z","timestamp":1763003343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721011660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2666636721011660"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.08.017","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}